Noah Kauff

Positions:

Instructor, Temporary in the Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1993

University of Pennsylvania

Grants:

Publications:

Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate.

Authors
Kauff, N; Robson, M
MLA Citation
Kauff, Noah, and Mark Robson. “Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate..” Nat Rev Clin Oncol, vol. 12, no. 9, Sept. 2015, pp. 505–06. Pubmed, doi:10.1038/nrclinonc.2015.130.
URI
https://scholars.duke.edu/individual/pub1327346
PMID
26196251
Source
pubmed
Published In
Nature Reviews. Clinical Oncology
Volume
12
Published Date
Start Page
505
End Page
506
DOI
10.1038/nrclinonc.2015.130

Screening for familial ovarian cancer: a ray of hope and a light to steer by.

Authors
Long, KC; Kauff, ND
MLA Citation
Long, Kara C., and Noah D. Kauff. “Screening for familial ovarian cancer: a ray of hope and a light to steer by..” J Clin Oncol, vol. 31, no. 1, Jan. 2013, pp. 8–10. Pubmed, doi:10.1200/JCO.2012.45.4678.
URI
https://scholars.duke.edu/individual/pub1327360
PMID
23213103
Source
pubmed
Published In
Journal of Clinical Oncology
Volume
31
Published Date
Start Page
8
End Page
10
DOI
10.1200/JCO.2012.45.4678

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

BACKGROUND: Patients with BRCA-associated ovarian cancer (OC) have a survival advantage over those with sporadic OC. To further explore this, we examined the impact of prognostic factors on disease-free survival (DFS) and overall survival (OS) in patients with known BRCA mutation status. PATIENTS AND METHODS: We reviewed stage III-IV OC patients treated at our institution between 1 December 1996 and 30 September 2006 and also tested on protocol for BRCA mutations. Impact on DFS and OS was determined by Kaplan-Meier analysis and a Cox proportional hazards model. RESULTS: Of the 110 patients, 36 had deleterious BRCA mutations [BRCA (+)] and 74 were BRCA wild type [BRCA(-)]. Thirty-one of 36 (86%) BRCA (+) and 60 of 74 (81%) BRCA (-) patients were platinum sensitive (P = 0.60). Median OS was longer for BRCA (+) patients (not reached versus 67.8 months; P = 0.02), but DFS was similar (26.9 versus 24.0, P = 0.3). On multivariate analysis, OS correlated with primary platinum sensitivity [HR = 0.15; 95% CI (confidence interval) 0.06-0.34] and BRCA (+) mutation status (HR = 0.33; 95% CI 0.12-0.86). CONCLUSIONS: BRCA mutation status predicted OS independent of primary platinum sensitivity, suggesting that underlying tumor biology contributes to disease outcome and may be worthy of consideration in future clinical trial design.
Authors
Gallagher, DJ; Konner, JA; Bell-McGuinn, KM; Bhatia, J; Sabbatini, P; Aghajanian, CA; Offit, K; Barakat, RR; Spriggs, DR; Kauff, ND
MLA Citation
Gallagher, D. J., et al. “Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity..” Ann Oncol, vol. 22, no. 5, May 2011, pp. 1127–32. Pubmed, doi:10.1093/annonc/mdq577.
URI
https://scholars.duke.edu/individual/pub1327405
PMID
21084428
Source
pubmed
Published In
Ann Oncol
Volume
22
Published Date
Start Page
1127
End Page
1132
DOI
10.1093/annonc/mdq577

Management of BRCA mutation-negative patients

© 2008 by Informa Healthcare USA, Inc. However, almost half of families with multiple cases of breast cancer only (site-specific breast cancer families) do not have an identifiable BRCA1 or BRCA2 mutation. l Reasons why families with multiple cases of breast cancer only may not have an identifiable BRCA1 or BRCA2 mutation include (i) the cluster of cancers is a chance event, (ii) the individual tested may be a phenocopy (i.e., the tested individual has a sporadic cancer unrelated to an inherited familial predisposition), (iii) the inherited predisposition is due to a mutation in an as yet undiscovered cancer predisposition gene, or (iv) currently used mutation techniques are unable to detect a mutation that is present within BRCA1 or BRCA2.
Authors
Gallagher, DJ; Kauff, ND
MLA Citation
Gallagher, D. J., and N. D. Kauff. “Management of BRCA mutation-negative patients.” Hereditary Gynecologic Cancer: Risk, Prevention and Management, 2008, pp. 107–15.
URI
https://scholars.duke.edu/individual/pub1361298
Source
scopus
Published Date
Start Page
107
End Page
115

Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

Women from site-specific hereditary breast cancer families who carry a BRCA1 or BRCA2 mutation are at increased risk for ovarian cancer. It is less clear, however, whether individuals from hereditary breast cancer families who do not carry such a mutation are also at increased ovarian cancer risk. To determine whether women from BRCA mutation-negative hereditary breast cancer families are at increased risk for ovarian cancer, 199 probands from BRCA mutation-negative, site-specific breast cancer kindreds who consented to prospective follow-up at the time of genetic testing were identified. The incidence of new breast and ovarian cancers in probands and their families since receipt of their genetic test results was determined by questionnaire. The expected number of cancers and standardized incidence ratios (SIRs) were determined from age-specific cancer incidence rates from the Surveillance, Epidemiology, and End Results (SEER) program by using the method of Byar. All statistical tests were two-sided. During 2534 women-years of follow-up in 165 kindreds, 19 new cases of breast cancer were diagnosed, whereas only 6.07 were expected (SIR = 3.13, 95% confidence interval [CI] = 1.88 to 4.89; P < .001), and one case of ovarian cancer was diagnosed, whereas only 0.66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer.
Authors
Kauff, ND; Mitra, N; Robson, ME; Hurley, KE; Chuai, S; Goldfrank, D; Wadsworth, E; Lee, J; Cigler, T; Borgen, PI; Norton, L; Barakat, RR; Offit, K
MLA Citation
Kauff, Noah D., et al. “Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families..” J Natl Cancer Inst, vol. 97, no. 18, Sept. 2005, pp. 1382–84. Pubmed, doi:10.1093/jnci/dji281.
URI
https://scholars.duke.edu/individual/pub1327425
PMID
16174860
Source
pubmed
Published In
J Natl Cancer Inst
Volume
97
Published Date
Start Page
1382
End Page
1384
DOI
10.1093/jnci/dji281